Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD).

Pawel MielnikJoseph SextonKaren M FagerliGunnstein BaklandYi HuEirik K KristianslundMari HoffAda WierødTore K Kvien

Published in: Rheumatology advances in practice (2023)

Our work has shown a similar AE profile of csDMARDs to previous data. However, higher discontinuation rates for SSZ and LEF cannot be explained easily from AE profiles.

Keyphrases

electronic health record
high dose
big data
low dose
data analysis